LILRB4/CD85k/ILT3 Protein, Human (Domain1&2, HEK293, His)

The LILRB4/CD85k/ILT3 protein is a key inhibitory receptor that plays a key role in immune regulation and tolerance. As a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, it inhibits receptor-mediated phosphorylation, intracellular calcium mobilization, and FCGR1A/CD64-mediated monocyte activation, thereby reducing TNF production. LILRB4/CD85k/ILT3 Protein, Human (Domain1&2, HEK293, His) is the recombinant human-derived LILRB4/CD85k/ILT3 protein, expressed by HEK293 , with C-His labeled tag. The total length of LILRB4/CD85k/ILT3 Protein, Human (Domain1&2, HEK293, His) is 192 a.a., with molecular weight of 23-25 kDa.

LILRB4/CD85k/ILT3, an inhibitory receptor, plays a pivotal role in immune regulation and the establishment of immune tolerance. Functioning as a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, this protein is involved in diverse cellular processes. It inhibits receptor-mediated phosphorylation of cellular proteins and the mobilization of intracellular calcium ions, and it further down-regulates FCGR1A/CD64-mediated monocyte activation, leading to reduced TNF production. Additionally, LILRB4/ILT3 impedes T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytotoxic T cells, and promoting the generation of CD8+ T suppressor cells. It induces the up-regulation of CD86 on dendritic cells and interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. The inhibitory effects are at least partially mediated through interactions with FN1 and the phosphatase PTPN6.

Human

HEK293

C-His

Q8NHJ6 (P27-S218)

11006  [NCBI]

23-25 kDa

Greater than 95% as determined by Tris-Bis PAGE.

<1 EU/μg, determined by LAL method.